Studying proteins that prevent blood clotting

The SHBG domain of protein S: its role as a functional regulator of the TFPI anticoagulant pathway

David A Lane (lead researcher)

Imperial College London

Start date: 01 November 2014 (Duration 3 years)

Blood clotting is a vital part of the healing process after injury. But if blood clots form in blood vessels they can block the flow of blood and cause diseases such as heart attacks or strokes. Finding new ways to prevent blood clotting could prevent or treat blood clots that lead to a heart attack or stroke.

Blood clotting is a complicated process involving many factors that are tightly controlled. Understanding exactly how this works is crucial to achieve the balance of blood clot prevention in heart and circulatory disease whilst still enabling the body to heal after injury.

Professor David Lane and his team at Imperial College London are experts in the blood clotting process. They have recently found that two proteins important for clotting called coagulation inhibitor tissue factor pathway inhibitor (TFPI) and protein S interact with each other through a region of protein S called the sex hormone binding globulin like domain (SHBG). Binding of TFPI to protein S through the SHBG is important for TFPI to have its ‘anti-clotting’ action. These proteins clearly play a key role in blood clotting and also interact with other proteins, but scientists don’t fully understand the intricate detail of these interactions.

Professor Lane’s team have been awarded a grant from the BHF to identify and study the interaction between these two proteins and perhaps reveal new ways to prevent blood clotting in heart and circulatory disease.

Project details

Grant amount £192,174
Grant type Project Grant
Start Date 01 November 2014
Duration 3 years
Reference PG/14/37/30855
Status Complete

< back to search results